MDV, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2023.

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

DaVita Inc. (DVA) Q3 2023 Earnings Call Transcript

Dialysis firm DaVita raises its full-year 2023 adjusted profit per share outlook after beating quarterly revenue estimates, on the back of strong demand, sending shares up nearly 6% in extended tra...

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

DaVita (NYSE: DVA) stock price has come under intense pressure in the past few days. The stock made a big dive on October 9th and crashed to a multi-month low of $71.45.

We know Warren Buffett likes to make big bets on business. Apple (NASDAQ: AAPL ) is famously one of the largest Warren Buffett stocks, accounting for nearly one-half of Berkshire Hathaway's (NYSE: ...

DENVER , Oct. 17, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, November 7, 2023, at 5:0...

Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatment for type 2 diabetes delayed the progression o...

Dialysis firm DaVita said on Thursday it believes that early success of Novo Nordisk's diabetes drug Ozempic in kidney disease trial will have "limited application" to overall patients suffering fr...

Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney dise...

Ozempic may find yet another clinical use. The drug, developed by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO ), has been making waves throughout the healthcare industry.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.